Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.

A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial ...

CagriSema is a once-weekly combination of semaglutide and cagrilinitide. For adults with overweight or obesity, weight loss was up to 22.7% in those without diabetes and 13.7% in those with diabetes.

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss—up to 24% with ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

CHICAGO — CagriSema, a new weekly injection from Novo Nordisk combining the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide, significantly reduced weight and improved ...

(RTTNews) - Novo Nordisk's (NVO) Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared to 2.3% ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss.

CagriSema, the dual agonist studied in REDEFINE 1 and 2, is designed to meet this need by targeting two key pathways: appetite regulation and blood glucose management.

The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7 ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss.